No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ABBV AbbVie
- 167.290
- -0.510-0.30%
Close Apr 25 16:00 ET
- 166.500
- -0.790-0.47%
Post 19:03 ET
296.21BMarket Cap61.50P/E (TTM)
169.290High165.570Low5.50MVolume167.660Open167.800Pre Close919.67MTurnover0.31%Turnover Ratio61.50P/E (Static)1.77BShares181.19652wk High28.59P/B294.67BFloat Cap125.84752wk Low5.92Dividend TTM1.76BShs Float181.196Historical High3.54%Div YieldTTM2.22%Amplitude20.362Historical Low167.138Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
PCE Inflation Data, ExxonMobil, Earnings: What to Watch
Express News | Cigna Says Biosimilar to Abbvie's Humira Will Be Available Through Agreements With Multiple Manufacturers
Cigna to Offer Humira Rivals With $0 Copay at Specialty Pharmacy
Express News | NYSE Order Imbalance 131290.0 Shares on Buy Side
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
Thursday, AbbVie Inc (NASDAQ:ABBV) released topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase 3b/4 study of upadacitinib (Rinvoq, 15 mg once daily starting dos
UPDATE 1-AbbVie's Skin Disease Drug Found to Be More Effective Than Regeneron's Dupixent in Study
Comments
My trading plan for April 2024 to July 2024.
Hello Mooers! 
Recently, there have been signs that World War 3
is coming (*1, *2, *3). Given the current status in the Middle East, Eastern Europe, and the Asia-Pacific, investing has become a difficult task.
In light of this hypothetical situation
, I have chosen to invest from April 2024 to July 2024 using a three-pronged strategy. 
Approach One: Buy the winners
Who are the winners? During wars, companies that are in the defense, oil, ...
Recently, there have been signs that World War 3
is coming (*1, *2, *3). Given the current status in the Middle East, Eastern Europe, and the Asia-Pacific, investing has become a difficult task. In light of this hypothetical situation
, I have chosen to invest from April 2024 to July 2024 using a three-pronged strategy. Approach One: Buy the winnersWho are the winners?
During wars, companies that are in the defense, oil, ...
28
26
$Novo-Nordisk A/S(NVO.US$ & $Eli Lilly and Co(LLY.US$ 's MCap increased by $285 bil in Q1 2024 alone, driven mostly by growth of the GLP-1 franchises,
Revenue from both companies GLP-1 drugs totaled $33.6 bil last yr, an impressive number that almost certainly will grow this yr,
But let's put that $285 bil incr in mkt value into perspective,
$AbbVie(ABBV.US$ has a $315 bil MCap, not much bigger than the combined Q1 incr in mkt value for LLY & NVO,
ABBV had $54 bil in revenue in 2023, compared ...
Revenue from both companies GLP-1 drugs totaled $33.6 bil last yr, an impressive number that almost certainly will grow this yr,
But let's put that $285 bil incr in mkt value into perspective,
$AbbVie(ABBV.US$ has a $315 bil MCap, not much bigger than the combined Q1 incr in mkt value for LLY & NVO,
ABBV had $54 bil in revenue in 2023, compared ...
4
Major acquisition announced YTD in 2024
A look at one of the major acquisition deals YTD…👇
$MRTX
Acquired By: Bristol-Myers Squibb$Bristol-Myers Squibb(BMY.US$
Date: Jan. 23, 2024
Price: $4.8B
$AbbVie(ABBV.US$$GlaxoSmithKline(GSK.US$
$MRTX
Acquired By: Bristol-Myers Squibb$Bristol-Myers Squibb(BMY.US$
Date: Jan. 23, 2024
Price: $4.8B
$AbbVie(ABBV.US$$GlaxoSmithKline(GSK.US$
4
1
🔥 M&A News 🔥
$AbbVie(ABBV.US$ to acquire $Landos Biopharma(LABP.US$
⇒ $137.5M deal at $20.42/sh 💰💰
⇒ strengthens portfolio in inflammatory & autoimmune diseases
⇒ Adds lead asset NX-13 (Ph2 trial UC)
$Nuvation Bio(NUVB.US$ to acquire AnHeart Therapeutics
⇒ all-stock transaction
⇒ transforms NUVB into late-stage global oncology company
⇒ Includes taletrectinib with ongoing trials NSCLC)
$Novo-Nordisk A/S(NVO.US$ to acquire Cardior Pharmaceuticals
⇒ 1.025 B euros deal 💰💰
⇒ strengthens pi...
⇒ $137.5M deal at $20.42/sh 💰💰
⇒ strengthens portfolio in inflammatory & autoimmune diseases
⇒ Adds lead asset NX-13 (Ph2 trial UC)
$Nuvation Bio(NUVB.US$ to acquire AnHeart Therapeutics
⇒ all-stock transaction
⇒ transforms NUVB into late-stage global oncology company
⇒ Includes taletrectinib with ongoing trials NSCLC)
$Novo-Nordisk A/S(NVO.US$ to acquire Cardior Pharmaceuticals
⇒ 1.025 B euros deal 💰💰
⇒ strengthens pi...
11
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Money Thrill : Instead of cash (cash is ONLY an paper without underlying value ! ) I buyed Amundi PHYSICAL GOLD ETC . Friday up 0.37 % ... and in 14 days 7 %. Chinese gouvernement buyed a lot of gold! LESSON > MONEY has only a Value because the COMMON TRUST in this PAPER. [Money Printing presses can make more] On the other hand, shares also have an intrinsic value better than paper money. Then choose the right one if war breaks out
Mars MoooOP Money Thrill:
profitpilot : Hold and observe. Don't buy the dip just because it's cheap. Cheap can be cheaper. Time the market (as best as you can).
Mars MoooOP profitpilot:
Cui Nyonya Kueh :
View more comments...